Hi cyberbash I would recommend that you take a look at the NOM...

Hi cyberbash

I would recommend that you take a look at the NOM which was dispatched yesterday....(see the ASX announcement dated yesterday 20/11/2015)

There is a report prepared by Valutech attached to the independent valuation which values Alcidion's intellectual property. This report by Valutech gives a very good description of the competitive environment facing Alcidion both in Aus and in the US. I would recommend reading this report in its entirety

The following excerpts from the Valutech report are a good starting point to answer your question as to how Alcidion will distinguish itself from the established US players

"The commercialisation approach adopted by Alcidion, is a more subtle and organic approach than that adopted by the larger Information technology providers in the industry such as Allscripts Healthcare Solutions which undertakes very large and costly implementation of its integrated platform with the potentials for substantial disruption and cost overruns.

The Alcidion approach is one in which implementation of its platform is a much lower risk undertaking, but once the confidence of the hospital client is gained, the relationship is likely to be very long term and provide economic returns over a long period where the financial costs are not regarded as onerous because commercial advantages of implementation of the platform can be demonstrated. The company has also formed partnerships with other healthcare providers so that joint solutions can be used in a number of different hospitals and countries........"

Hope this helps

Cheers